BZO-CHMOXIZID

BZO-CHMOXIZID (CHM-MDA-19) is a synthetic cannabinoid compound first reported in 2008 in the same series as the better known derivative MDA-19.[1] It started to be widely sold as an ingredient in grey-market synthetic cannabis blends in 2021 following the introduction of legislation in China which for the first time introduced general controls on various classes of synthetic cannabinoids,[2] but did not include the group to which MDA-19 and BZO-CHMOXIZID belong. While BZO-CHMOXIZID is the most potent compound at CB1 from this so-called "OXAZID" series, it is still markedly CB2 selective and of relatively low potency at CB1, with an EC50 of 84.6 nM at CB1 compared to 2.21 nM at CB2.[3][4]

BZO-CHMOXIZID
Identifiers
  • N'-[(3Z)-1-(Cyclohexylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC22H23N3O2
Molar mass361.445 g·mol−1
3D model (JSmol)
  • O=C(C1=CC=CC=C1)N/N=C(C2=O)/C3=CC=CC=C3N2CC4CCCCC4
  • InChI=1S/C22H23N3O2/c26-21(17-11-5-2-6-12-17)24-23-20-18-13-7-8-14-19(18)25(22(20)27)15-16-9-3-1-4-10-16/h2,5-8,11-14,16H,1,3-4,9-10,15H2,(H,24,26)/b23-20-
  • Key:HTPDZRIIOLCPPS-ATJXCDBQSA-N

References
  1. Diaz P, Xu J, Astruc-Diaz F, Pan HM, Brown DL, Naguib M (August 2008). "Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain". Journal of Medicinal Chemistry. 51 (16): 4932–47. doi:10.1021/jm8002203. PMID 18666769.
  2. "关于将合成大麻素类物质和氟胺酮等18种物质列入《非药用类麻醉药品和精神药品管制品种增补目录》的公告" [Announcement on the inclusion of 18 substances including synthetic cannabinoids and fluamine in the "Additional Catalogue of Controlled Varieties of Non-medicinal Narcotics and Psychotropic Drugs"]. Ministry of Public Security of the People's Republic of China (in Chinese). 12 May 2021.
  3. Deventer MH, Van Uytfanghe K, Vinckier IM, Reniero F, Guillou C, Stove CP (September 2022). "Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists". Drug Testing and Analysis. 14 (9): 1565–1575. doi:10.1002/dta.3283. PMID 35560866. S2CID 248777773.
  4. Lee KZ, Wang Z, Fong CY, Goh EM, Moy HY, Chan EC (November 2022). "Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID, and BZO-CHMOXIZID for Illicit Abuse Monitoring". Clinical Chemistry. 68 (11): 1436–1448. doi:10.1093/clinchem/hvac138. PMID 36175111.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.